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Cystic Fibrosis (CF) is the most common lethal rare genetic disease in the Caucasian populations.
It is caused by a variety of sequence alterations in the Cystic Fibrosis Transmembrane Regulator
(CFTR) gene. In Caucasian, one over 3,500 new born children suffers from the disease and one
over 30 of them is at least carrier of a severe mutation in the CFTR gene. CF and CFTR-related
disorders (CFTR-RDs) are two distinct clinical outcomes of the gene mutations. The CF mutation
induces a severe phenotype involving different organs, whereas a CFTR-RD mutation induces less
life-threatening symptoms with threemain clinical entities including congenital bilateral absence of
the vas deferens (CBAVD), acute recurrent or chronic pancreatitis, and disseminated bronchiectasis
(Bombieri et al., 2011).
In the Arab countries, the spectrum of CF mutations, incidence and prevalence of the disease
are largely unknown in the Arab populations (Wei et al., 2006). This is due to the lack of disease
awareness, and diagnosis facilities that mislead the identification of CF during many decades.
Additionally, epidemiological studies that realized were revealed a distinguished mutational
spectrum between Arab countries if compared toWhite-European populations. Furthermore, Arab
Mediterranean countries have a different CFTR mutational profile if compared to the Arabian
Peninsula.
Egypt as Mediterranean North African country, this strategic position attracted many invaders
throughout its history. Therefore, in addition to its Pharaonic origin, gene flow to its population
occurred from the Ethiopian, Greco-Roman, Arab, Turkish, French and English settlers (Temtamy
et al., 2010). The common heritage among the countries bordering the Mediterranean is not
restricted to historical or cultural aspects. There are considerable commonalities in the gene pools
of the Mediterranean Northern and Southern countries. This “genetic sharing” has resulted from
considerable human movements (i.e., migration, invasion, and trade) throughout history in this
area (Temtamy et al., 2010). Consequently, Egypt is not like other Arab countries and mutations in
theCFTR gene have been influenced by gene flow coming from different populations. Furthermore,
the high rate of consanguinity, infant and neonatal mortality in the Egyptian society will, therefore,
increase CF incidence and private mutations. Indeed, another important issue is the increase
number of CFTR-related disorders patients such as idiopathic bronchiectasis, congenital bilateral
absence of the vas deferens, idiopathic (non-alcoholic) pancreatitis, and severe sinusitis in the
Egyptian population. This observation is in agreement with data previously published (Lissens
et al., 1999; Hussein et al., 2011; Fathy et al., 2016).
In Egypt, there is no available data on the nature and frequency of CF gene mutations.
There are a few previous reports of CFTR gene mutations in Egyptian patients that
have been published. In these papers, a CF screening strategy of CFTR mutations was
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realized using commercial kits or a panel defined by the
American College of Medical Genetics and Genomics (ACMG)
and American College of Obstetricians and Gynecologists
(ACOG), (Naguib et al., 2007; El-Falaki et al., 2014; Fathy et al.,
2016; Shahin et al., 2016), which is not suitable for screening
of the CFTR gene mutations in the Egyptian population. This
emphasizes the need for establishing a correct genetic screening
for CF mutations in Egyptian patients and to determine the
carrier status in their healthy relatives.
In our recent study, we have performed a complete CFTR
gene screening in CF or CFTR-RD patients from Alexandria,
Northern Egypt, by direct sequencing of the entire CFTR gene
that identified four novel CF mutations in the CFTR gene
amongst 13 other known mutations in the other populations
(Figure 1A). Furthermore, this is the first comprehensive profile
of CFTR gene mutations and their corresponding haplotypes
in the Egyptian population (El-Seedy et al., 2016). Besides,
FIGURE 1 | Mutational spectrum of CFTR gene mutations in the Egyptian population. (A) CFTR mutations identified in our recent investigation of Egyptian CF
or CFTR-RD patients from Alexandria city, Northern Egypt which performed a complete CFTR gene screening by direct sequencing of the entire CFTR gene. This
study is the first to identify novel mutations (indicated with a star*) in the Egyptian population amongst 13 other known mutations that appear to be a specific to
Egyptian CF patients (2); (B) a panel of the most common mutations detected in the Egyptian population; (C) intronic mutations identified in the Egyptian patients that
will be also present in the panel.
CFTR mutations in the other Egyptian regions have not been
analyzed. Thus, the identification of CFTR mutations is become
increasingly important in genetic counseling and prenatal
diagnosis particularly in families with multiple affected children
(Wang et al., 2000).
According to available data of CFTR gene mutations,
we propose general national screening panel comprising 27
mutations reported in Egyptian patients until now. This will
help to detect about 50% of CFTR gene mutations in Egypt and
further extensive studies will help to improve this panel. The
establishment of the first panel of the CFTR gene mutations in
the Egyptian population (Figures 1B,C) will help physicians for
designing an appropriate strategy for future genetic diagnosis for
patients and families at risk.
In this regard, defining a population-specific mutational
panel for CF in Egyptian population including: c.92G>A
(exon 2), c.454A>T (exon 4), c.902A>G (exon 8), c.1418delG
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(exon 11), c.2620-15C>G (intron 15), c.2782G>C (exon
17), c.2997_3000delAATT (exon 19), c.3154T>G (exon 20),
c.3718-24G>A (intron 23), c.3872A>G (exon 23), c.3877G>A
(exon 24), c.4207A>G (exon 26), c.4242+10T>C (intron
26) mutations identified in our recent study (Figure 1A),
and together with previously reported mutations in Egyptian
patients (Figures 1B,C) [c.1766+3A>C (intron 13), c.1993A>T
(exon 14), c.3909C>G (exon21), c.1521_1523delCTT (exon11),
(Naguib et al., 2007); c.54-5940_273+10250del21kb (intron 1-
exon 3), c.443T>C (exon 4), c.1040G>C (exon8), c.1364C>A
(exon10), c.1652G>A (exon12), c.2051_2052delAAinsG (exon
14), c.3067_3072delATAGTG (exon19), c.3484C>T (exon 22),
c.3846G>A (exon 23), (Shahin et al., 2016); c.1040G>C (exon
8), c.1364C>A (exon 10), c.3484C>T (exon 22), c.3752G>A
(exon 23), c.3846G>A (exon 23), (Fathy et al., 2016)] should
be highly recommended for Egyptian patients. However, full
clinical manifestations of additional CF and CFTR-RDs patients
could lead to clarify the pathogenicity of these mutants in this
population.
The overall purpose of this paper, in our opinion, is to
develop and validate a strategy for increasing the sensitivity of
CFTR screening in Egyptian population. This strategy includes
establishing of an Egyptian CF Registry Network (ECFRN)
where there is no reliable estimates on the number of CF
patients and clinical pattern as well as the most common CFTR
mutations in this population. Hence, this registry is essential
in order to have data about prevalence and incidence of CF in
Egypt for improving clinic diagnostic outcomes and planning
health policies. In addition, an extensive molecular analysis of
CFTR gene using next-generation sequencing (NGS) technology
combined withmultiplex ligation-dependent probe amplification
(MLPA) will provide a wider coverage of the CFTR locus and
expand our proposed panel in CF molecular diagnosis.
In summary, our findings confirm the importance of direct
gene sequencing of the entire CFTR gene in combination
with molecular and functional studies (in isolation and
in complex alleles) in order to perform a correct genetic
counseling and to estimate the prevalence of the carriers in
the general population. Moreover, collaborative studies, on
the clinical and fundamental levels, are necessary to give an
adequate genotype-phenotype correlation. Thus, sharing the
obtained data between CFTR laboratories, clinical research
centers and concerned communities in Egypt are also from
a great importance to ensure a progression in mutation
researches and to help clinicians in giving a suitable prenatal
diagnosis, patients advising and treatments prescription when
available.
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